Alanine Aminotransferase: A Clinical and Regulatory Tool for Detecting Liver Injury–Past, Present, and Future

Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH)

(2011) Paul B. Watkins et al.   DRUG SAFETY

Circulating microRNAs as potential markers of human drug-induced liver injury

(2011) Philip J. Starkey Lewis et al.   HEPATOLOGY

Upper limits of normal for alanine aminotransferase activity in the United States population

(2011) Constance E. Ruhl et al.   HEPATOLOGY

New FDA Regulation to Improve Safety Reporting in Clinical Trials

(2011) Rachel Behrman Sherman et al.   NEW ENGLAND JOURNAL OF MEDICINE

The existence of a relationship between increased serum alanine aminotransferase levels detected in premarketing clinical trials and postmarketing published hepatotoxicity case reports

(2010) L. LLANOS et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Recommendations to qualify biomarker candidates of drug-induced liver injury

(2010) Josef S Ozer et al.   Biomarkers in Medicine

Causality assessment in drug-induced liver injury using a structured expert opinion process: Comparison to the Roussel-Uclaf causality assessment method

(2010) Don C. Rockey et al.   HEPATOLOGY

Alanine aminotransferase: Is it healthy to be “normal”?

(2009) D. Robert Dufour   HEPATOLOGY

Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease

(2008) John G. Weil et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY